Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pan American Health Organization | OTHER |
| Catholic University of the Sacred Heart | OTHER |
| Diabetes Frail Ltd | OTHER |
| University of Castilla-La Mancha |
Not provided
Not provided
Not provided
Not provided
Randomized clinical trial, international, multicentre, single-blind, two parallel groups, pragmatic. It will be carried out by investigators in several Latin American countries (Chile, Colombia, Mexico and Peru) and with random allocation 1:1 of the participants to Usual Care Group (UCG) or Intervention Group (IG). Each country will select 5 trial sites that will recruit 0-60 participants. Finally, 1050 subjects will be involved in the project.
The primary outcome are the changes in function and quality of life as measured by changes in the scores used to assess them between baseline and 1-year follow-up. Function will be assessed by the Short Physical Performance Battery-SPPB.
This study is focused on an older population (≥ 65 years) with diabetes and a frail or prefrail status
The intervention includes:
Educational program in small groups: 7 sessions in the clinical trial sites (2 sessions a week for the first 3-4 weeks) Exercise program (16 weeks): learning phases in clinical trial site for 3-4 first week (coincident with the educational program sessions) and the rest at home.
Adaptation of targets of HbA1c and blood pressure (BP). UCG Usual care group consists in level of care usually given in Health Care system.
International, multicentre, single-blind, two parallel groups, pragmatic randomised Research Clinical Trial. It will be carried out by investigators in several Latin American countries (Chile, Colombia, Mexico and Peru) and with random allocation 1:1 of the participants to Usual Care Group (UCG) or Intervention Group (IG). Each country will select 5-7 trial sites that will recruit 51 participants (255 participants per country) except Mexico which will select 2 sites to recruit 50 participants each one (100 participants).
There will be a National lead investigator in each involved country. This National lead investigator will be trained by the general coordinator team in the procedures of the study. Each National lead investigator will be responsible for the training in his/her country. In each country, the lead will select the recruitment trial sites (5-7 in each country) and each trial site will recruit 51 participants approximately except in Mexico (see above). All data will be collected in an eCRF (electronic case report form) platform designed specifically for this project.
This study is focused on an older population (≥ 65 years) with diabetes and a frail or prefrail status.
Objectives:
Main objective: To assess the effectiveness of a multi-modal intervention in subjects with type 2 Diabetes Mellitus aged ≥ 65 years who are frail or pre-frail in terms of function and quality of life in comparison with usual clinical practice.
Secondary objectives:
Usual care group:
Usual clinical practice is the level of usual health care that a patient with diabetes receives from their local national health system.
Intervention group:
Optimal glycosylated hemoglobin range between 7.6-8.5% (60-69 mmol/mol) and optimal blood pressure: <150/90 mmHg
Physical exercise program that will be used will be the Vivifrail program, developed in Europe (Erasmus + UE). Vivifrail includes:
Nutritional and educational program: The intervention is designed to increase diabetes knowledge, develop practical self-care skills for diabetes, and increase the likelihood of improving glycemic control safely. The intervention aims to minimize the risk of hypoglycemia, ensure optimal nutritional status, and help maintain functional status.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | Multimodal intervention: |
|
| Usual care group | Placebo Comparator | Usual care group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Multimodal intervention | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in physical function | (SPPB scale)The primary outcome is the difference in function after 12 months of follow-up between the intervention group and usual clinical practice measured by changes in the Short Physical Performance Battery (SPPB) scale. SPPB scores between 0-12. 0 is the worse and 12 the best value. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Frailty trajectories | Trajectories of frailty according to changes in Fried´s phenotype. Frieds Phenotype scores between 0 and 5. 0 means robust; 1-2 mean prefrail and 3 or more mean frail | 1 year |
| Frailty trajectories |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| LEOCADIO RODRIGUEZ-MAÑAS, PhD | Consorcio Centro de Investigación Biomédica en Red (CIBER) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital San Ignacio_Universidad Javeriana | Bogotá | 11001 | Colombia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| Confederación Española de Organizaciones de Mayores (CEOMA) | UNKNOWN |
| Pontificia Universidad Javeriana | OTHER |
| Pontificia Universidad Catolica de Chile | OTHER |
| Instituto Nacional de Geriatria, Mexico | OTHER_GOV |
| Universidad de San Martín de Porres (USMP) | UNKNOWN |
| Universidad de Santiago de Chile | OTHER |
he DIABFRAIL-LATAM is an open randomized clinical trial, with random allocation 1:1 by participants to Usual Care Group (UCG) or Intervention Group (IG)
Not provided
Not provided
Not provided
Not provided
|
| Usual care group | Other | The level of usual health care that a patient with diabetes receives from their local national health system |
|
Trajectories of frailty according to changes frail trait scale (FTS). FTS scores between 0-50. 0 is the best value and 50 the worst value.
| 1 year |
| Frailty trajectories | Trajectories of frailty according to changes in FRAIL scale. FRAIL scores SPPB scores between 0-5. 0 means robust; 1-2 mean prefrail and 3 or more mean frail | 1 year |
| Basic activities of daily living | Deterioration of basic activities of daily living (BADL) according to changes in at least 10 points of Barthel index. Barthel scores between 0-100; 0 is the worst value and 100 the best. | 1 year |
| Instrumental activities of daily living | Deterioration of instrumental activities of daily living (IADL) according to changes in at least 1 point of Lawton scale. Lawton scale scores between 0-10; 0 is the worst and 10 the best value | 1 year |
| Rate of Hypoglycemia | Episodes of symptomatic hypoglycemia (proven glycaemia below 4mmol/L, or signs and symptoms attributed to hypoglycemia that respond to specific treatment) and hypoglycemic coma | 1 year |
| Number of Hospital admission | Episodes of hospital admission (any overnight admission) | 1 year |
| Number of patients with Permanent institutionalization | Permanent Institutionalization yeas or not | 1 year |
| Rate of Falls | Number of falls | 1 year |
| Rate of Severe Falls | Number of severe falls (2 or more falls in the year or at least 1 fall that requires medical assistance) | 1 year |
| Caregiver burden | Caregiver burden (if exist) evaluated by the Zarit scale (ZBI). The ZBI consists of 22 items rated that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88.9 Higher scores indicate greater burden. | 1 year |
| Rate of mortality | Number of patients who died | 1 year |
| Health-related quality of life | Changes in Participant Health-related quality of life evaluated by EuroQoL 5D 3L(European Quality of life). EuroQoL scores between 0-10 and 10 is the worse quality of life. | 1 year |
| ID | Term |
|---|---|
| D000073496 | Frailty |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided